Please login to the form below

White paper helps industry navigate new NHS roadmap

New report shows how pharma can support the NHS in the Covid-19 recovery era

As the pandemic response in the UK moves on to ‘phase 3’, and the NHS plans to make a gradual return to pre-Covid-19 service levels, pharma must define how its products and services fit into the new roadmap that has been created.

In a bid to answer some of these questions for industry, healthcare intelligence provider Wilmington Healthcare has published a white paper, entitled “Covid-19: Roadmap to Recovery”.

The white paper looks at the next stages in the recovery process for the NHS and explores how industry can support the health service as it faces a multitude of challenges, including dealing with the care backlog and Covid-19 aftercare.

It covers three major areas, the first two of which are the NHS Reset initiative and its attendant policies; followed by the status and aims of the various NHS stakeholders tasked with taking the service through the next phase.

It also tackles issues surrounding NHS recovery from the point of view of pharma and defines the issues that are affecting it from access and digital engagement to the role of new NHS pathways.

The need to respond at scale and pace to the coronavirus pandemic has created unprecedented collaboration between the NHS and pharma in areas such as protection of supply chains and rapid development of Covid-19 drugs and vaccines. The challenge now is to maintain and strengthen partnership working.

Oli Hudson, Content Director at Wilmington Healthcare and one of the authors of the white paper, saidAs the NHS resets, it will require innovation, technology, new pathways and new solutions to the various issues emerging from Covid-19. Industry needs to identify the right stakeholders and develop propositions tailored to their changing needs.

“With the right brand strategy and approach, some very promising new partnerships can be formed. This white paper aims to give industry powerful insights into the opportunities that are emerging and help it define how to support the NHS through the challenges that lie ahead.”

To register to download the free white paper visit http://ow.ly/yY3C30r5auA

Ends

24th August 2020

Share

Tags

Company Details

Wilmington Healthcare

01268 495600

Contact Website

Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom

Latest content on this profile

White paper helps industry navigate new NHS roadmap
New report shows how pharma can support the NHS in the Covid-19 recovery era
Wilmington Healthcare
Covid-19 drives change in long-term conditions management
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home
Wilmington Healthcare
Covid-19: how is it impacting on the NHS Long-term Plan?
Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the plan but put others in jeopardy
Wilmington Healthcare
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it
Wilmington Healthcare
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve
Wilmington Healthcare
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond
Wilmington Healthcare